The MIT cell therapy spinout priced its shares at the bottom of their range to raise $70.6m, following some $166m in venture funding.

SQZ Biotechnologies, a US-based cellular medicine developer based on research conducted at Massachusetts Institute of Technology (MIT), has floated in a $70.6m initial public offering. The offering consisted of just over 4.4 million shares issued on the New York Stock Exchange (NYSE) and priced at $16.00 each at the foot of the IPO’s $16 to $18 range.…

The rest of this content is only accessible to Global University Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.